Show simple item record

dc.contributor.authorOtieno, F. G.
dc.contributor.authorFalk, M.J.
dc.contributor.authorLi, D.
dc.contributor.authorGai, X.
dc.contributor.authorMcCormick, E.
dc.contributor.authorPlace, E.
dc.contributor.authorLasorsa, F.M.
dc.contributor.authorHou, C.
dc.contributor.authorKim, C.E.
dc.contributor.authorAbdel-Magid, N.
dc.contributor.authorVazquez, L.
dc.contributor.authorMentch, F.D.
dc.contributor.authorChiavacci, R. M.
dc.contributor.authorLiang, J.
dc.contributor.authorLiu, X.
dc.contributor.authorJiang, H.
dc.contributor.authorGiannuzzi, G.
dc.contributor.authorMarsh, E.D.
dc.contributor.authorYiran, G.
dc.contributor.authorTian, L.
dc.contributor.authorPalmieri, F.
dc.contributor.authorHakonarson, H.
dc.date.accessioned2014-11-18T08:53:56Z
dc.date.available2014-11-18T08:53:56Z
dc.date.issued2014
dc.identifier.citationJIMD Rep. 2014;14:77-85. doi: 10.1007/8904_2013_287.en_US
dc.identifier.issn2192-8304
dc.identifier.other2192-8312
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213340/pdf/978-3-662-43748-3_Chapter_314.pdf
dc.identifier.urihttp://ir-library.ku.ac.ke/handle/123456789/11693
dc.descriptionReviseden_US
dc.description.abstractBACKGROUND: Whole exome sequencing (WES) offers a powerful diagnostic tool to rapidly and efficiently sequence all coding genes in individuals presenting for consideration of phenotypically and genetically heterogeneous disorders such as suspected mitochondrial disease. Here, we report results of WES and functional validation in a consanguineous Indian kindred where two siblings presented with profound developmental delay, congenital hypotonia, refractory epilepsy, abnormal myelination, fluctuating basal ganglia changes, cerebral atrophy, and reduced N-acetylaspartate (NAA). METHODS: Whole blood DNA from one affected and one unaffected sibling was captured by Agilent SureSelect Human All Exon kit and sequenced on the Illumina HiSeq2000. Mutations were validated by Sanger sequencing in all family members. Protein from wild-type and mutant fibroblasts was isolated to assess mutation effects on protein expression and enzyme activity. RESULTS: A novel SLC25A12 homozygous missense mutation, c.1058G>A; p.Arg353Gln, segregated with disease in this kindred. SLC25A12 encodes the neuronal aspartate-glutamate carrier 1 (AGC1) protein, an essential component of the neuronal malate/aspartate shuttle that transfers NADH and H(+) reducing equivalents from the cytosol to mitochondria. AGC1 activity enables neuronal export of aspartate, the glial substrate necessary for proper neuronal myelination. Recombinant mutant p.Arg353Gln AGC1 activity was reduced to 15% of wild type. One prior reported SLC25A12 mutation caused complete loss of AGC1 activity in a child with epilepsy, hypotonia, hypomyelination, and reduced brain NAA. CONCLUSIONS: These data strongly suggest that SLC25A12 disease impairs neuronal AGC1 activity. SLC25A12 sequencing should be considered in children with infantile epilepsy, congenital hypotonia, global delay, abnormal myelination, and reduced brain NAA.en_US
dc.language.isoenen_US
dc.titleErratum to: AGC1 Deficiency Causes Infantile Epilepsy, Abnormal Myelination, and Reduced N-Acetylaspartateen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record